Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa study of ruxolitinib in regularly transfused thalassemia patients
2013-002812-28Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ruxolitinib in Thalassaemia, sponsored by Novartis. Primary endpoint: Percent change in RBC transfusion requirement. Started Feb 2014; status: completed.
02
Drugs
03
Conditions
Thalassaemia
Beyond the preview
Go deeper on 2013-002812-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002812-28.